Compare ADMA Biologics Inc (ADMA) vs Intuit Inc. (INTU) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Intuit (INTU) trades at $272.14, down 1.17% on the day, amid a bearish technical signal and ongoing securities fraud investigations. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $12.80 versus $12.57 expected, and robust profitability with a net income margin of 21.91%. Revenue growth is steady, climbing from $12.7B in 2022 to $18.8B in 2025, supported by a high gross profit margin of 79.96%.

Despite solid fundamentals, INTU faces significant headwinds from legal scrutiny and negative sentiment, with a 20% stock drop triggering multiple fraud probes. Analyst consensus remains bullish with a $433.69 price target, but near-term risks from litigation and competitive pressures in tax software could limit upside. The stock's current valuation at a P/E of 16.6 offers a margin of safety if growth persists.